Wolking v. Lindner

District Court, M.D. Pennsylvania·Decided May 3, 2024·No. 3:23-cv-00806·Unknown

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF PENNSYLVANIA

: STACEY WOLKING and DARYL WOLKING, : Plaintiffs CIVIL ACTION NO. 3:23-cv-806 : v. (JUDGE MANNION) : HENRY LINDNER and YOUNGS APOTHECARY, INC., d/b/a : TUNKHANNOCK COMPOUNDING CENTER, :

Defendants :

MEMORANDUM

Plaintiffs, who claim that Defendant Tunkhannock Compounding Center was negligent in its care of Stacey Wolking, (Doc. 1), have requested from Defendant certain information relating to other patients, (Doc. 45), to which requests TCC objects. (Doc. 46). The court ordered that the parties submit supplemental briefing regarding this request, (Doc. 47), and they have done so. (Doc. 48; Doc. 49).

I. THE CLAIMS The Complaint alleges that Stacey Wolking met with Dr. Henry Lindner once in person, and thereafter consulted him by email and phone, for advice and treatment related to her symptoms of fatigue, brain fog, and malaise. (Doc. 1 ¶9–11). Dr. Lindner diagnosed her with babesiosis, an infection caused by a babesia parasite, “without ever confirming his diagnosis with a

blood smear examination or a PCR test,” which practice is “standard” for doctors in the U.S. (Id. ¶12–16). He prescribed her a combination of antimicrobial medications and corticosteroids. (Id. ¶¶20, 29). He also told

Stacey that he had diagnosed his daughter Valerie with babesiosis and had developed the treatment program for her. (Id. ¶28). Despite Stacey’s complaints of severe adverse side effects, Dr. Lindner prescribed her increasingly higher dosages of corticosteroids, (Id.

¶¶31–60), often dosages significantly higher than a reasonable physician would typically prescribe. (Id. ¶32). He informed Stacey that his daughter Valerie had also taken high dosages of corticosteroids and had suffered

adverse side effects. (Id. ¶34, 37, 53). During the course of this treatment, Lindner directed Stacey to fill her prescriptions at TCC instead of her local pharmacy, telling her that her local pharmacy might complain to the medical board about the high doses. (Id.

¶71). TCC provided Stacey “with the equivalent of 19,000 milligrams of prednisone in a period of less than two months.” (Id. ¶74). Defendants’ conduct “caused Stacey to suffer severe physical and

emotional pain and distress that she became suicidal, refused all medical treatments, asked her doctors to allow her to die, and spent approximately two days in hospice care at Loudoun Hospital” in Virginia. (Id. ¶75). Plaintiffs

claim that TCC provided Ms. Wolking with corticosteroid prescriptions “which they knew or should have known were excessive, dangerous, inappropriate, and/or improper”; that TCC did so “in violation of the rules, regulations,

practices, policies, and/or guidelines in place for the dispensing of prescription corticosteroids by a licensed pharmacy”; and that it “failed to exercise due diligence in its professional capacity” by not contacting Dr. Lindner about the unreasonably high dosages, taking steps to correct his

error, or refusing to fill such prescriptions. (Id. ¶¶96–98). Sadly, Dr. Lindner’s daughter Valerie passed away in December 2023. (Doc. 30). Her obituary states that “[s]he lost her long battle with a tick-borne

disease.” (Doc. 31).

II. THE REQUEST Plaintiffs requested that Defendant:

 [D]escribe the prescriptions written by Henry Lindner which were filled at Tunkhannock Compounding Center in 2020, 2021, and 2022: the total number, the drug types and dosages, and the amount billed and earned by Tunkhannock Compounding Center as a result of these prescriptions. (Doc. 45-1 ¶12).  [Produce the following]: o All documents showing the corticosteroid prescriptions dispensed to Valerie Lindner in 2021 and 2022, including patient history documents and prescription documents. (Doc. 45-2 ¶1). o Records in PK dispensing software showing manufacturer of corticosteroids dispensed to Valerie Lindner and Stacey Wolking in 2021 and 2022. (Id. ¶2). o Any and all emails or other communication between Dr. Henry Lindner and any TCC employee, in 2020 and the present, concerning his babesiosis patients and/or corticosteroid dosing and/or his treatment of Valerie Lindner for babesiosis. (Id. ¶4). o Any and all emails or other communications between TCC employees in 2020 and the present, concerning Dr. Lindner’s babesiosis patients and/or corticosteroid dosing and/or Dr. Lindner’s treatment of Valerie Lindner for babesiosis. (Id. ¶5). o Records or data showing total amounts of prednisone, dexamethasone, and any other corticosteroid acquired and dispensed by TCC in 2021 and 2022, and manufacturers or each drug and entities from which they were acquired by TCC. (Id. ¶6).  [Designate officers authorized to testify as to]: o Corticosteroid prescriptions dispensed to/for the benefit of Valerie Lindner, (Doc. 45-3 ¶d); o History of prescriptions written by Dr. Henry Lindner and filled by TCC, including amounts earned by TCC from Dr. Lindner’s prescriptions from 2013–2022, (Id. ¶e); o Manufacturer of prednisone and dexamethasone dispensed to Stacey Wolking and/or Valerie Lindner, identity of any entity from which prednisone and dexamethasone were purchased by TCC, (Id. ¶L); o Total amounts of prednisone, dexamethasone, and any other corticosteroid acquired and dispensed by TCC in 2021 and 2022, and manufacturers of each drug and entities from which they were acquired by TCC, (Id. ¶m); o Percentage of TCC revenue attributable to corticosteroids, and to prescriptions written by Dr. Henry Lindner, in 2021 and 2022. (Id. ¶n).

(See Doc. 45). Defendant objects to these requests. (Doc. 46). III. LEGAL STANDARD Parties to a civil action “may obtain discovery regarding any

nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case, considering the importance of the issues at stake in the action, the amount in controversy, the parties’ relative

access to the relevant information, the parties’ resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit.” Fed. R. Civ. P. 26(b). A request is relevant “if there is any possibility that the information may be

relevant to the general subject matter of the action.” Kegerise v. Susquehanna Twp. Sch. Dist., Civ. No. 1:CV-14-0747, 2016 WL 2736048, at *1 (M.D. Pa. May 11, 2016). “Information within the scope of discovery

need not be admissible in evidence to be discoverable.” Rule 26(b). “A party may move for an order compelling disclosure or discovery.” Fed. R. Civ. P. 37(a)(1). The initial burden is on the moving party to demonstrate that the requested discovery falls within Rule 26(b)’s scope.

Schiavone v. Luzerne County, 243 F.R.D. 34, 37 (M.D. Pa. 2023). If this burden is met, the nonmoving party must demonstrate that that the requested discovery is not within Rule 26’s scope or is not sufficiently

relevant to justify the burden of producing it. Id. IV. THE OBJECTIONS TCC contends that the requested discovery is irrelevant, not

proportional to the needs of the case, privileged under the HIPAA Privacy Rule, and not discoverable under Pennsylvania law. (Doc. 48 at 7–10). Because information protected by the Privacy Rule may be disclosed

pursuant to a court order, 45 C.F.R. §164.512(f)(1)(ii)(A), the court need not address that ground of objection again. (See Doc. 47 at 3). A. Relevance TCC asserts that because Valerie Lindner is not a party to this case,

Free access — add to your briefcase to read the full text and ask questions with AI

Wolking v. Lindner, (M.D. Pa. 2024).

Wolking v. Lindner (Wolking v. Lindner) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Buckman v. Verazin
54 A.3d 956 (Superior Court of Pennsylvania, 2012)
Lykes v. Yates
77 A.3d 27 (Superior Court of Pennsylvania, 2013)
Gail v. New England Gas Co.
243 F.R.D. 28 (D. Rhode Island, 2007)